PTO/SB/106 (3-00)
Approved for use through 10/31/02. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## Declaration and Power of Attorney for Patent Application

## 特許出頭宣言書及び委任状

Japanese Language Declaration

日本語宜言書		
私は、以下に記名された発明者として、ここに下記の通り宣言する:	As a below named inventor, I hereby declare that:	
· 私の住所、郵便の宛先そして国籍は、私の氏名の後に記載された適りである。	My residence, post office address and citizenship are as stated next to my name.	
下記の名称の発明について、特許請求範囲に記載され、且つ特許が 求められている発明主題に関して、私は、最初、最先且つ唯一の発明 者である(唯一の氏名が記載されている場合)が、成いは最初、最先 且つ共同発明者である(複数の氏名が記載されている場合)と信じて いる。	I believe I am the original, first and sole inventor (If only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled	
	BODY WEIGHT GAIN INHIBITOR	
上記発明の明細書はここに遂付されているが、下記の額がチェック されている場合は、この区りでない:	the specification of which is attached hereto unless the following box is checked:	
□の日に出版され、 この出版の米国出版番号をたはPC丁国際出版番号は、であり、且つの日に潜正された出版(該当する場合)	was filed on December 25, 2003 as United States Application Number or PCT International Application Number PCT/JP2003/016656 and was amended on (if applicable).	
私は、上記の袖正書によって補正された、特許既求範囲を含む上記 明細書を検討し、且つ内容を理解していることをここに表明する。	I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.	
私は、連邦規則法典第37編規則1、58に定義されている、特許 性について重要な情報を関示する最野があることを認める。	I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.58.	

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the need of the individual case. Any comments on the amount of time you are required to complete this form should be sent to Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks, Washington, DC 20231.

Page 1 of 4

## Japanese Language Declaration (日本語宜言書)

私は、ここに、以下に記載した外国での特許出顧または発明者証の 出取、或いは米国以外の少なくとも一国を指定している米国法典語3 5 展第365条 (a)によるPCT国際出版について、同第119条 (a)

I hereby claim foreign priority under Title 35, United States Code, Section 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application

優先板を主張する本出版の出版	ついて放光版を主張するとともに、 日よりも前の出版日を有する外国での 一般いはPCT国際出版については、 チェックすることにより示した。	which designated at least one coun listed below and have also identified any foreign application for patent or International application having a fill application for which priority is claim	t below, by checking the box, inventor's certificate, or PCT ing date before that of the
Prior Foreign Application(s) 外国での先行出頭			Priority Claimed 優先権主張
380386/2002	Japan	27/12/2002	⊠ Yes □ No
(Number) (哲号)	(Country) (阻名)	(Day/Month/Year Filed) (出版日/月/年)	はい いいえ
			☐ Yes ☐ No
(Number) (番号)	(Country) (因名)	(Day/Month/Year Filed) (出版日/月/年)	はい いいえ
私は、ここに、下記のいかなる 国法典第35編119条 (e) 項の	米国仮特許出版についても、その米 利益を主張する。	I hereby claim the benefit under Title 119(e) of any United States provision	35. United States Code, Section nal application(s) listed below.
(Application No.) (出版者号)	(Filing Date) (出版日)	(Application No.) (出版賽号)	(Filling Date) (出版日)
奥那35掲第日 20条に赤いでは、 東那35掲第四 出版について、 を主張する。また、本ののでは、 35板 田田 はない 国際 はない の名 定い 国際 出版 はない		I hereby claim the benefit under Title 120 of any United States applications international application designating the and, insofar as the subject matter of application is not disclosed in the primiternational application in the manne of Title 35, United States Code Section to disclose information which is materials. Title 37, Code of Federal Regulations available between the filling date of the national or PCT International filing date.	(s), or 385(c) of any PCT the United States, listed below each of the claims of this or United States or PCT or provided by the first paragraph on 112, I acknowledge the duty rial to patentability as defined in the Section 1.56 which became the prior application and the
PCT/JP2003/016656	December 25, 2003	Pending	
(Application No.) (出版君号)	(Filing Date) · (出版日)	(Status: Patented, Pending, Aban (理双:特許許可、任屆中、放	
(Application No.) (出版番号)	(Flung Date) (出版日)	(Status: Patented, Pending, Aband (現況:特許許可、任医中、放	
且つ情報と信ずることに基づく謎を宣言し、さらに、故意に虚偽の 第18脳第1001条に基づき、 により処罰をれ、またそのような	の知識に係わる既述が真実であり、 述が、真実であるとほじられること 既述などを行った場合は、米国法典 新金をたは拘禁、若しくはその関方 故窓による遺偽の歴述は、本出版ま なる特許も、その有効性に関題が生 われたことを、ここに宜言する。	I hereby dectare that all statements me knowledge are true and that all statements and belief are believed to be true; and were made with the knowledge that we like so made are punishable by fine of Section 1001 of Title 18 of the United with false statements may jeopardize or any patent lessued thereon.	nents made on information of further that these statements vitful taise statements and the r imprisonment, or both, under States Code and that such

PTO/SB/106 (5-00)

Approved for use through 10/3 1/02. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

•	Japanese Lang (日本語)	uage Declaration 宜音書)
委任状: 私は本出版を審査する手続を行いの全ての果務を遂行するために、記名をれい ほ士及び/または弁理士を任命する。(氏: こと)	に発明者として、下記の#	the following attempted andies asserted to assert the second
書頭送付先		Send Correspondence to:  Mark Chao, PhD. JD.  Intellectual Property Department  Takeda Pharmaceuticals North America, Inc.  Suite 500, 475 Half Day Road  Lincolnshire, IL 60069 USA
直通電話連絡先:(氏名及び電話番号)	·	Direct Telephone Calls to: (name and telephone number) Mark Chao, PhD. JD. Voice: (847)383-3391 Fax: (847)383-3481 Elaine M. Ramesh, PhD. JD. Voice: (847)383-3391 Fax: (847)383-3481
唯一または第一発明者氏名	(10)	Full name of sole or first inventor  Zen-ichi TERASHITA
発明者の著名	日付	inventor's signature  Date  Date
住所		Residence c/o Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8686 Japan
<b>国程</b>		Citizenship Japan
多便の現先		Post Office Address Same as above
第二共同発明者がいる場合、その氏名	2-00	Full name of second joint inventor, if any Keiji KUSUMOTO
第二共同発明者の署名	EM	Second inventor's signature Date    Community   May 24, 2005
生所		Residence c/o Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 32-8686 Japan
ı.		Citizenship Japan
事任の宛先		Post Office Address Same as above
第三以下の共岡発明者についても同様に記: すること)	成し、 署名を	(Supply similar information and signature for third and subsequent local inventors.)

PTO/SB/106 (5-00)
Approved for use through 10/31/02. OMB 0631-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE collection of information unless it displays a valid OMB control number.

第三共同発明者がいる場合、その氏名  Eff  第三共同発明者の署名  Eff  第三共同発明者の署名  Eff  第三共同発明者の署名  Eff  第四共同是明者の署名  Eff  Residence / C Takeda Pharmaceut. Limited, 17-85, Jusohomachi 2- Yodogava-ku, Osaka-Shi, Osaka-Shi Same as above  第四共同発明者がいる場合、その氏名  第四共同発明者の署名  Eff  Full name of foorth joint inventor, if any Yoshimi IMURA 第四共同発明者の署名  Eff  Residence / C Takeda Pharmaceut. Limited, 17-85, Jusohomachi, 2- Yoshimi IMURA 第四共同発明者の署名  Eff  Residence / C Takeda Pharmaceut. Limited, 17-85, Jusohomachi, 2- Yoshimi IMURA  第四共同発明者の署名  Eff  Residence / C Takeda Pharmaceut.  第四共同発明者がいる場合、その氏名  CREaseNew  Fourth inventor, if any Yoshimi IMURA  Residence / C Takeda Pharmaceut. Limited, 17-85, Jusohomachi, 2- Yodogava-ku, Osaka-Shi, Os	
第三共同是明者の著名  Eff Third inventor's signature  Automorphism Management Managem	24, 20
展示 Amazouch Maracutic Limited、17-85、Jushonmachi 2- Yodogawa-ku, Osaka-shi, Osaka 33	
Limited, 17-85, Jusohomachi, 2-Yodogawa-ku, Osaka-shi, Osaka-shi	in I Compa
超位の発光 Post Office Address Same as above Sa	chome,
第四共同発明者がいる場合、その氏名  中間 name of fourth joint inventor, if any Yoshimi IMURA  第四共同発明者の署名  日刊  Fourth inventor's signature  May 2  Residence of To Takeda Pharmaceutic Limited, 17-85, Jusohommachi, 2-19 dogawa-ku, Osaka-shi, Osaka-Siz Cittenship  Japan  Fost Office Address Same as above	J&
第四共同発明者がいる場合、その氏名  日刊  Full name of foorth joint inventor, if any Yoshimi IMURA  第四共同発明者の著名  日刊  Full name of foorth joint inventor, if any Yoshimi IMURA  Fourth inventor's signature  May 2  Residence of 7 Takeda Pharmaceutic Limited, 17.85, Jusohomachi 2-7 Yodogawa-ktu, Osaka-shi, Osaka S32  Giffenship  Japan  Full name of foorth joint inventor, if any Yoshimi IMURA  Full name of foorth joint inventor, if any Yoshim	
Yoshimi IMURA 第四共同発明者の署名 日刊 Fourth inventor's signature May 2 Residence C/o Takeda Pharmaceutic Limited, 17-85, Jusohonmachi, 2-イ Yodogawa-ku, Osaka-Shi, Osaka-Shi  Chirenship  Japan  Fost Office Address Same as above	
Yoshimi IMURA Fourth inventor's signature May 2 Residence C/O Takeda Pharmaceutic Limited, 17-85, Jusohonmachi, 2-イ Yodogawa-ku, Osaka-Shi, Osaka-Saz  Citizenship  Japan  Fost Office Address Same as above	
第四共同発明者の署名 日代 Fourth inventor's signature May 2 Residence で /o Takeda Pharmaceutic Limited, 17-85, Jusohonmachi, 2-7 Yodogawa-Kr., Osaka-shi, Osaka 532 日代 「Othership Japan Fost Office Address Same as above	
May 2 Residence C/O Takeda Pharmaceutic Limited, 17-85, Jusohonmachi, 2- Yodogawa-ku, Osaka-shi, Osaka-Si2  Gitzenship  Japan  Post Office Address same as above	Date
Limited, 17-85, Jusohomachi 2-6 Yodogawa-ku, Osaka-shi, Osaka 532  Image: Japan  Post Office Address Same as above	4, 2005
Japan  Fost Office Address Same as above	nome.
same as above	JPX
	<del></del>
	٠